Pacira(US:PCRX)2026-02-26 21:16Revenue Performance - Total net product sales increased by 4% to $722.854 million in 2025, compared to $697.186 million in 2024[532] - EXPAREL revenue rose by 5% to $575.130 million in 2025, driven by a 6% increase in gross vial volume[532] - ZILRETTA revenue decreased by 1% to $116.633 million in 2025, primarily due to a 4% decrease in kit volume[533] - iovera° sales increased by 6% to $24.178 million in 2025, attributed to a 7% increase in Smart Tip volume[533] Cost and Margin Analysis - Cost of goods sold decreased by 12% to $149.749 million in 2025, improving gross margin to 79% from 76% in 2024[535] - Gross margin increased by three percentage points in 2025 compared to 2024, primarily due to lower EXPAREL inventory reserves and improved ZILRETTA product costs[536] Research and Development - Total research and development (R&D) expenses increased by 44% in 2025, amounting to $117.3 million, which is 16% of total revenue[539] - Clinical and preclinical development expenses rose by 57% to $52.9 million in 2025, driven by increased trial activities and personnel[540] - Product development expenses increased by 44% to $44.2 million, including a $5.0 million upfront license payment for PCRX-2002[541] Operating Expenses - Total selling, general and administrative expenses increased by 25% to $368.8 million, representing 51% of total revenue[545] - Sales and marketing expenses grew by 32% to $226.6 million, reflecting investments in customer awareness and expanding the sales force[546] - General and administrative expenses rose by 15% to $100.3 million, primarily due to increased headcount and legal fees[547] Legal and Settlement Matters - Legal settlement costs of $7.0 million were recognized in 2025 related to patent infringement suits[557] - A legal judgment of $23.1 million was recorded as other income, resulting from a court ruling requiring the repayment of previously paid royalties[558] - An impairment of $25.9 million was recorded for in-process research and development associated with the ZILRETTA shoulder asset due to revised timelines[559] Financial Performance - The company reported a net loss of $6.6 million, primarily due to an impairment of an equity investment and convertible note receivable[565] - Income tax expense decreased by 73% to $9.8 million in 2025 from $36.5 million in 2024, with an effective tax rate of 58%[566] Cash Flow and Financing - Net cash provided by operating activities was $152.0 million in 2025, down from $189.4 million in 2024, due to increased operating expenses[573] - Net cash provided by investing activities was $99.5 million in 2025, reflecting significant sales of available-for-sale investments[575] - Net cash used in financing activities was $369.6 million in 2025, primarily due to the maturity of the 2025 Notes and share repurchases[577] - The company anticipates needing additional debt or equity financing to meet future operating and capital requirements, with no committed external sources of funds currently available[596] Shareholder and Equity Matters - The company repurchased 2.0 million shares for $50.0 million in Q4 2025 as part of its share repurchase program[523] - The company has raised $344.5 million in net proceeds from the sale of common stock and other equity securities since its inception[580] Commitments and Contingencies - The company has potential milestone payments of up to $372.3 million to former Flexion stockholders if certain regulatory and commercial milestones are met by December 31, 2030[600] - As of December 31, 2025, the company has net minimum commitments of $53.5 million for operating leases, with $12.8 million due in 2026[598] Interest and Debt Management - Interest income increased by 15% in 2025 to $5.3 million, driven by a legal judgment and GQ Bio note receivable investment[562] - Interest expense rose by 5% due to the completion of a project and the issuance of 2029 Notes, partially offset by lower interest rates[563] - A loss of $1.0 million was recognized on early extinguishment of debt in 2025, compared to a gain of $7.5 million in 2024[564] - As of December 31, 2025, the company has $287.5 million in aggregate principal amount due on its 2029 notes, with remaining interest payments of $21.2 million[597] Goodwill and Fair Value - The company’s goodwill balance was $20.2 million as of December 31, 2025, resulting from the GQ Bio Acquisition in February 2025[612] - The estimated fair value of the 2029 notes was $1,010 per $1,000 principal amount as of December 31, 2025, with all $287.5 million of principal remaining outstanding[616] Risk Factors - Accounts receivable are primarily concentrated with three large wholesalers of pharmaceutical products, posing a risk of material adverse impact on financial condition in case of non-performance or non-payment[619]